Methods of making compounds having a beta-adrenergic inhibitor and a linker and methods of making compounds having a beta-adrenergic inhibitor, a linker and a phosphodiesterase inhibitor
WO2008019106A1
Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
US2007066619A1
Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
US2008090827A1
Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
CA2588947A1
Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
WO2005035505A2
Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
WO2005016885A2
COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE
MXPA05006975A
CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST beta-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE.
AU2003297562A1
COMPOUNDS WITH MIXED PDE-INHIBITORY AND Beta-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
EP1573045A2
Heart failure gene determination and therapeutic screening
CA2501534A1
Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity
